Literature DB >> 19719828

Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A.

G Castaman1, M E Mancuso, S H Giacomelli, A Tosetto, E Santagostino, P M Mannucci, F Rodeghiero.   

Abstract

BACKGROUND: The relationship of the biologic response to desmopressin with the F8 mutation and physiological characteristics has been poorly investigated in patients with mild hemophilia A.
OBJECTIVES: We prospectively assessed the molecular and phenotypic determinants of the biologic response to desmopressin in a cohort of 50 patients with mild hemophilia A.
METHODS: Up to 24 h after desmopressin, blood samples were serially obtained and factor (F)VIII and von Willebrand factor (VWF) measured. The promoter region, all exons and exon-intron boundaries of the F8 gene were screened using denaturing high-performance liquid chromatography (DHPLC). Direct sequencing was done when DHPLC screening was normal. Genomic DNA was also sequenced for exons 18-21, 24 and 27 of VWF.
RESULTS: Mean basal FVIII:C was 19 +/- 9 IU dL(-1) (range 6-37) and the median postdesmopressin peak increase was 2.5-fold (range 1.1-7.1). Eleven patients with a cross-reacting material positive (CRM(+)) phenotype had similar basal levels and relative increases of FVIII:C to the remaining patients with low FVIII:Ag. Using multivariate regression, FVIII:C half-life was positively related to basal and peak VWF:Ag levels (P = 0.008) and patient age (P = 0.004). Eleven patients had evidence of reduced FVIII survival. While 27 different gene mutations were identified in 41 patients, nine patients had no detectable mutation. These patients had significantly smaller peaks and smaller relative increase of postdesmopressin FVIII:C (median FVIII:C 26 IU dL(-1) vs. 54 IU dL(-1); P < 0.001; fold 1.8 +/- 0.6 vs. 2.9 +/- 0.8; P = 0.002).
CONCLUSIONS: In this cohort of patients with mild hemophilia A, a poor biologic response to desmopressin was frequently associated with the absence of detectable F8 mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19719828     DOI: 10.1111/j.1538-7836.2009.03595.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

Review 1.  Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.

Authors:  Giancarlo Castaman; Karin Fijnvandraat
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

Review 2.  Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project.

Authors:  B A Konkle; J M Johnsen; M Wheeler; C Watson; M Skinner; G F Pierce
Journal:  Haemophilia       Date:  2018-05       Impact factor: 4.287

3.  Reccurrent F8 Intronic Deletion Found in Mild Hemophilia A Causes Alu Exonization.

Authors:  Yohann Jourdy; Alexandre Janin; Mathilde Fretigny; Anne Lienhart; Claude Négrier; Dominique Bozon; Christine Vinciguerra
Journal:  Am J Hum Genet       Date:  2018-01-18       Impact factor: 11.025

4.  Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.

Authors:  Qizhen Shi; Scot A Fahs; Erin L Kuether; Brian C Cooley; Hartmut Weiler; Robert R Montgomery
Journal:  Blood       Date:  2010-07-06       Impact factor: 22.113

5.  Desmopressin in moderate hemophilia A patients: a treatment worth considering.

Authors:  Janneke I Loomans; Marieke J H A Kruip; Manuel Carcao; Shannon Jackson; Alice S van Velzen; Marjolein Peters; Elena Santagostino; Helen Platokouki; Erik Beckers; Jan Voorberg; Johanna G van der Bom; Karin Fijnvandraat
Journal:  Haematologica       Date:  2018-01-05       Impact factor: 9.941

6.  Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.

Authors:  Lisette M Schütte; Marjon H Cnossen; Reinier M van Hest; Mariette H E Driessens; Karin Fijnvandraat; Suzanne Polinder; Erik A M Beckers; Michiel Coppens; Jeroen Eikenboom; Britta A P Laros-van Gorkom; Karina Meijer; Laurens Nieuwenhuizen; Evelien P Mauser-Bunschoten; Frank W G Leebeek; Ron A A Mathôt; Marieke J H A Kruip
Journal:  BMJ Open       Date:  2019-04-23       Impact factor: 2.692

7.  Desmopressin for bleeding in non-severe hemophilia A: Suboptimal use in a real-world setting.

Authors:  Anne-Fleur Zwagemaker; Fabienne R Kloosterman; Michiel Coppens; Samantha C Gouw; Sara Boyce; Catherine N Bagot; Erik A M Beckers; Paul Brons; Giancarlo Castaman; Jeroen Eikenboom; Shannon Jackson; Marieke J H A Kruip; Frank W G Leebeek; Karina Meijer; Laurens Nieuwenhuizen; Ingrid Pabinger; Karin Fijnvandraat
Journal:  Res Pract Thromb Haemost       Date:  2022-08-31

8.  Hemophilia management: Huge impact of a tiny difference.

Authors:  Fabienne Kloosterman; Anne-Fleur Zwagemaker; Amal Abdi; Samantha Gouw; Giancarlo Castaman; Karin Fijnvandraat
Journal:  Res Pract Thromb Haemost       Date:  2020-02-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.